1. Scrip
  2. >>Business
  3. >>Deals

HAYA To Complement Lilly’s Metabolic Disease Efforts With Long Non-Coding RNA

 
• By Joseph Haas

HAYA, a pioneer in lncRNA, is teaming up with Lilly to discover novel targets and programmable RNA therapies for obesity and metabolic disorders.

Dark genome
HAYA is partnering with Lilly on dark genome-derived therapies • Source: Shutterstock

Long non-coding RNA (lncRNA) is an emerging therapeutic modality that may offer actionable novel targets in a variety of disease settings, and Eli Lilly and Company, already a leader in obesity and metabolic disease, is partnering with the Swiss biotech HAYA Therapeutics, SA in a multiyear discovery collaboration to find new therapeutic targets and preclinical candidates within the “dark genome.”

Key Takeaways

  • Focused on the dark genome and long non-coding RNA therapeutics, HAYA is partnering with Lilly to discover novel targets to address obesity and metabolic disease.

  • The deal follows a week after a Bayer/NextRNA alliance focused on lncRNA small molecule therapies for cancer

The two firms announced their collaboration, with an estimated total value of up to $1bn for HAYA, on 4 September. Just a week earlier, Bayer AG inked a licensing agreement with Boston’s NextRNA Therapeutics, Inc. to investigate lncRNA approaches to small molecule therapy for cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.